JD HEALTH Aktie

 

Nomura anticipated JD HEALTH (06618.HK)'s 4FQ25 revenue to rise by 22% YoY to RMB20 billion, exceeding market expectations due to heightened demand for pharmaceuticals driven by a surge in influenza cases during the period.Combining a 1.6 ppts YoY increase in non-IFRS operating profit margin for 3FQ, the broker expected JD H......

Nomura has released a report predicting JD HEALTH (06618.HK) to have beaten market expectations in 2H25, thanks to increased demand for pharmaceuticals as a result of a surge in flu cases in 4Q25.In Nomura's estimate, JD HEALTH would report a YoY growth of 22% in its 4Q25 revenue to RMB20 billion on the strength of the 30%/ ......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

HSTECH Top 5 Strongest Stocks in 2025:Stock | Change in Shr Price This YrHUA HONG SEMI (01347.HK) | +243.2%HORIZONROBOT-W (09660.HK) | +140.6%SMIC (00981.HK) | +124.7%JD HEALTH (06618.HK) | +97.5%BABA-W (09988.HK) | +77.5%HSTECH Top 5 Weakest Stocks in 2025:Stock | Change in Shr Price This YrMEITUAN-W (03690.HK) | -31.9%LI AUTO-......

US bourse elevated on Friday (12th) before ebbing back, with the DJIA diving 245 points or 0.5% after hitting a record high. Hong Kong stocks opened lower this morning (15th), mirroring the trend of external market. The HSI opened 258 points lower, or 1%, at 25,718; the HSCEI opened 99 points lower, or 1.1%, at 8,980; and the HS......

JD HEALTH (06618.HK) announced a deepened collaboration with Hong Kong's traditional nourishing food brand, HK JEBN. By pre-positioning ready-to-eat bird's nest products in JD LOGISTICS (02618.HK)'s Chongqing bonded warehouse, the logistic delivery time is expected to improve by 100%, enabling same-day delivery to Ch......

JD HEALTH (06618.HK) entered into a cooperation agreement with Wuhan University People's Hospital (Hubei General Hospital) to engage in in-depth collaboration across multiple areas, including home visits for rapid testing, telemedicine and health education, with an aim to jointly explore a new integrated development model of......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

JD HEALTH (06618.HK) announced that it had signed a strategic cooperation agreement with Boehringer Ingelheim Animal Health (Shanghai) under the umbrella of the global drugmaker Boehringer Ingelheim.According to their partnership, the two parties plan to leverage JD HEALTH's extensive pharmaceutical supply chain and medical ......

JD-SW (09618.HK) is weighing an issuance of bonds linked to JD HEALTH (06618.HK)'s equity, with an expected size of at least USD1 billion, Bloomberg reported, quoting people familiar with the matter. However, JD-SW has negated related rumors by clarifying that the information is false. ~AASTOCKS Financial NewsWebsite: www.aa......

JD-SW (09618.HK) is considering raising at least USD1 billion through the issuance of equity-linked bonds, which can be converted into JD HEALTH (06618.HK) shares, Bloomberg reported, citing sources. It is understood that JD-SW is now gauging investor interest.According to JD HEALTH's interim report, JD-SW holds over 67% of ......

Morgan Stanley released a research report lifting its target price for JD HEALTH (06618.HK) from $60 to $68.8, based on a discounted cash flow valuation, with rating kept at Equalweight.After considering JD HEALTH's 3Q25 results, the broker believed that the Company benefits from growth in direct sales and service revenue, a......

Find insight on Nuvalent, JD Health International, Bumrungrad Hospital and more in the latest Market Talks covering Health Care....

JD HEALTH (06618.HK)'s 3Q25 revenue and profit beat expectations, with revenue YoY growth accelerating from 24.5% in 1H25 to 28.7% in 3Q25, according to UBS' research report. UBS believed that this is mainly due to the strong growth in drug sales, a significant pick up in the health supplement business and a relatively l......

According to Nomura's research report, JD HEALTH (06618.HK)'s 3Q25 results were exceptional, with total revenue, driven by YoY increases of 30%/ 30%/ around 15% in pharmaceutical/ nutritional product/ medical device sales, growing by 29% YoY to RMB17 billion, 4% higher than the broker's estimate.Nomura raised its FY2......

Die Papiere von JD Health sind im heimischen Handel um knapp sieben Prozent angesprungen und notieren damit nur noch minimal unter ihrem Jahreshoch. Auslöser für den Anstieg waren die jüngsten Quartalszahlen. Sowohl beim Umsatz als auch beim Gewinn konnte der Konzern nicht nur den Markt, sondern auch die Analysten von Morgan Stanley überzeugen....

JD HEALTH (06618.HK) management, confident in achieving or even surpassing its 2025 annual revenue growth target of 22%, has raised its adjusted net profit target to RMB6.2 billion from around RMB5.6-5.7 billion, according to a report from Morgan Stanley.JD HEALTH's 3Q25 revenue increased by 28.7% YoY to RMB17.1 billion, 4% ......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

JD HEALTH (06618.HK) announced its third-quarter results for the period ending September 30, with revenue of RMB17.12 billion, up 28.7% YoY. Non-IFRS cwas RMB1.378 billion, up 59.9% YoY. Non-IFRS profit grew 42.4% to RMB1.902 billion.During the third quarter of 2025, JD Health entered into strategic cooperation agreements with l......

CLOUDR (09955.HK) announced that the Company entered into a service cooperation agreement with JD HEALTH (06618.HK) to expand online sales and service channels for Remifemin and other P2M pipeline products.The Company said that JD Health boasts a substantial user base and extensive platform resources. Meanwhile, the Company poss......